Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan;10(1):63-77.
doi: 10.1586/erv.10.152.

Progress in filovirus vaccine development: evaluating the potential for clinical use

Darryl Falzarano  1 , Thomas W Geisbert, Heinz Feldmann
Affiliations
Review

Progress in filovirus vaccine development: evaluating the potential for clinical use

Darryl Falzarano et al. Expert Rev Vaccines. 2011 Jan.

Abstract

Marburg and Ebola viruses cause severe hemorrhagic fever in humans and nonhuman primates. Currently, there are no effective treatments and no licensed vaccines; although a number of vaccine platforms have proven successful in animal models. The ideal filovirus vaccine candidate should be able to provide rapid protection following a single immunization, have the potential to work postexposure and be cross-reactive or multivalent against all Marburg virus strains and all relevant Ebola virus species and strains. Currently, there are multiple platforms that have provided prophylactic protection in nonhuman primates, including DNA, recombinant adenovirus serotype 5, recombinant human parainfluenza virus 3 and virus-like particles. In addition, a single platform, recombinant vesicular stomatitis virus, has demonstrated both prophylactic and postexposure protection in nonhuman primates. These results demonstrate that achieving a vaccine that is protective against filoviruses is possible; the challenge now is to prove its safety and efficacy in order to obtain a vaccine that is ready for human use.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Map of filovirus occurrences worldwide
Zaire ebolavirus (ZEBOV): red; Sudan ebolavirus (SEBOV): blue; Cote d’Ivoire ebolavirus (CIEBOV): purple; Reston ebolavirus (REBOV): green; Bundibugyo ebolavirus (BEBOV): yellow; Lake Victoria marburgvirus (MARV): black. The inset shows an enlarged view of equatorial Africa where the majority of filovirus infections occur.
Figure 2
Figure 2. Transmission of filoviruses
The proposed reservoirs for both Ebola and Marburg viruses are a number of species of African fruit bats. Multiple outbreaks have been associated with locations where contact with or the consumption of bats has occurred. Contact with infected nonhuman primates, typically as bush meat, has also been a suspected source of infection. While the mechanism of transmission from bats to humans and nonhuman primates is not known, transmission from nonhuman primates to humans is likely through contact with blood and tissues during butchering or from bites and scratches. Transmission between humans probably occurs via direct contact with blood or secretions; however, there is limited evidence of aerosol transmission. In the event of an act of bioterrorism the most likely route of infection would be by the aerosol route.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

  • Marburg virus disease: A summary for clinicians.
    Kortepeter MG, Dierberg K, Shenoy ES, Cieslak TJ; Medical Countermeasures Working Group of the National Ebola Training and Education Center's (NETEC) Special Pathogens Research Network (SPRN). Kortepeter MG, et al. Int J Infect Dis. 2020 Oct;99:233-242. doi: 10.1016/j.ijid.2020.07.042. Epub 2020 Aug 3. Int J Infect Dis. 2020. PMID: 32758690 Free PMC article. Review.
  • Advanced vaccine candidates for Lassa fever.
    Lukashevich IS. Lukashevich IS. Viruses. 2012 Oct 29;4(11):2514-57. doi: 10.3390/v4112514. Viruses. 2012. PMID: 23202493 Free PMC article. Review.
  • Progress of vaccine and drug development for Ebola preparedness.
    Choi WY, Hong KJ, Hong JE, Lee WJ. Choi WY, et al. Clin Exp Vaccine Res. 2015 Jan;4(1):11-6. doi: 10.7774/cevr.2015.4.1.11. Epub 2015 Jan 30. Clin Exp Vaccine Res. 2015. PMID: 25648233 Free PMC article. Review.
  • A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
    Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM. Phoolcharoen W, et al. Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20695-700. doi: 10.1073/pnas.1117715108. Epub 2011 Dec 5. Proc Natl Acad Sci U S A. 2011. PMID: 22143779 Free PMC article.
  • Ebolavirus and Haemorrhagic Syndrome.
    Matua GA, Van der Wal DM, Locsin RC. Matua GA, et al. Sultan Qaboos Univ Med J. 2015 May;15(2):e171-6. Epub 2015 May 28. Sultan Qaboos Univ Med J. 2015. PMID: 26052448 Free PMC article. Review.
See all "Cited by" articles

References

    1. Feldmann H, Geisbert T, Jahrling P, et al. Filoviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA, editors. Virus Taxonomy: Eighth Report of the International Committee on the Taxonomy of Viruses. Elsevier; San Diego, CA, USA: 2005. pp. 645–653.
    1. Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol Med. 2006;12(5):206–215. - PubMed
    1. Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nature Rev. 2003;3(8):677–685. - PubMed
    1. Sanchez A, Geisbert TW, Feldmann H. Filoviridae: Marburg and Ebola viruses. In: Knipe DM, Howley PM, Griffin DE, et al., editors. Fields’ Virology. Lippincott Williams and Wilkins; PA, USA: 2007. pp. 1409–1448.
    1. Bray M, Mahanty S. Ebola hemorrhagic fever and septic shock. J Infect Dis. 2003;188(11):1613–1617. - PubMed

Publication types

MeSH terms